Literature DB >> 25054018

Expression of vimentin filaments in canine malignant mammary gland tumors: A simulation of clinicopathological features of human breast cancer.

Sanaz Rismanchi1, Orly Yadegar2, Samad Muhammadnejad3, Saeid Amanpour1, Masoud Taghizadeh-Jahed4, Ahad Muhammadnejad5.   

Abstract

Canine malignant mammary gland tumors (CMMGTs) are the most common malignancies observed in females. Several biological similarities have been reported between CMMGTs and human breast cancer (HBC). The present study aimed to assess the correlation of vimentin filaments overexpression, as part of the process of epithelial-mesenchymal transition (EMT) and the clinicopathological characteristics in CMMGTs. The clinicopathological characteristics of 42 CMMGTs were collected. Paraffin-embedded blocks underwent immunohistochemistry staining, which was performed using vimentin (to assess the evolution of the EMT process), Ki-67 (for evaluation of tumor proliferation) and cluster of differentiation 34 (CD34) (for evaluation of angiogenesis) antibodies. The tumor stage, grade, vascular invasion, margin status, rate of expression of the vimentin filaments, microvessel density-CD34 and proliferation rate data were obtained. Finally, the association between the expression of the vimentin filaments and those parameters was resolved statistically. A significant association was shown between the overexpression of the vimentin filaments and tumor size (r=0.71, P=0.03), tumor grade (r=0.80, P=0.021), angiogenesis (r=0.57, P=0.043), proliferation coefficient (r=0.06, P=0.001) and vascular invasion (r=0.76, P=0.043). Vimentin overexpression did not statistically correlate with the tumor stage or the margin status. Similar to the findings of the present study, certain recent studies have indicated that vimentin filament expression in HBC and CMMGTs is associated with the severity of cancer. Thus, spontaneous canine mammary tumor models appear to be an appropriate animal model for breast cancer research, and the results of the present study could aid to reinforce the association.

Entities:  

Keywords:  breast neoplasms; epithelial-mesenchymal transition; intermediate filaments; mammary neoplasms

Year:  2014        PMID: 25054018      PMCID: PMC4106566          DOI: 10.3892/br.2014.312

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  17 in total

1.  Canine mammary tumours as a model to study human breast cancer: most recent findings.

Authors:  Felisbina Luisa Queiroga; Teresa Raposo; Maria Isabel Carvalho; Justina Prada; Isabel Pires
Journal:  In Vivo       Date:  2011 May-Jun       Impact factor: 2.155

2.  Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.

Authors:  Peeter Karihtala; Päivi Auvinen; Saila Kauppila; Kirsi-Maria Haapasaari; Arja Jukkola-Vuorinen; Ylermi Soini
Journal:  Breast Cancer Res Treat       Date:  2013-02-15       Impact factor: 4.872

3.  Classification and grading of canine mammary tumors.

Authors:  M Goldschmidt; L Peña; R Rasotto; V Zappulli
Journal:  Vet Pathol       Date:  2011-01       Impact factor: 2.221

4.  Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer.

Authors:  B B da Silva; P V Lopes-Costa; A R dos Santos; E C de Sousa-Júnior; A P Alencar; C G Pires; M A Rosal
Journal:  Eur J Gynaecol Oncol       Date:  2009       Impact factor: 0.196

5.  Vimentin as a poor prognostic factor for triple-negative breast cancer.

Authors:  Nami Yamashita; Eriko Tokunaga; Hiroyuki Kitao; Yuichi Hisamatsu; Kenji Taketani; Sayuri Akiyoshi; Satoko Okada; Shinichi Aishima; Masaru Morita; Yoshihiko Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-26       Impact factor: 4.553

6.  Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters.

Authors:  A Hemalatha; T N Suresh; M L Harendra Kumar
Journal:  Indian J Cancer       Date:  2013 Jul-Sep       Impact factor: 1.224

7.  Transforming growth factor-β transiently induces vimentin expression and invasive capacity in a canine mammary gland tumor cell line.

Authors:  K Yoshida; T Saito; A Kamida; K Matsumoto; K Saeki; M Mochizuki; N Sasaki; T Nakagawa
Journal:  Res Vet Sci       Date:  2012-11-23       Impact factor: 2.534

8.  Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count.

Authors:  Hari Prasad Dhakal; Assia Bassarova; Bjørn Naume; Marit Synnestvedt; Elin Borgen; Rolf Kaaresen; Ellen Schlichting; Gro Wiedswang; Karl-Erik Giercksky; Jahn M Nesland
Journal:  Histol Histopathol       Date:  2009-08       Impact factor: 2.303

9.  The gene expression profiles of canine mammary cancer cells grown with carcinoma-associated fibroblasts (CAFs) as a co-culture in vitro.

Authors:  Magdalena Król; Karol M Pawłowski; Katarzyna Szyszko; Henryk Maciejewski; Izabella Dolka; Elisabetta Manuali; Michał Jank; Tomasz Motyl
Journal:  BMC Vet Res       Date:  2012-03-27       Impact factor: 2.741

10.  Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study.

Authors:  Andreia A Santos; Célia C Lopes; Jorge R Ribeiro; Liliana R Martins; Joana C Santos; Irina F Amorim; Fátima Gärtner; Augusto J Matos
Journal:  BMC Vet Res       Date:  2013-01-04       Impact factor: 2.741

View more
  3 in total

1.  MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors.

Authors:  Eman S Ramadan; Noha Y Salem; Ibrahim A Emam; Naglaa A AbdElKader; Haithem A Farghali; Marwa S Khattab
Journal:  Vet Res Commun       Date:  2021-11-17       Impact factor: 2.459

2.  Celastrol Inhibits Canine Mammary Tumor Cells by Inducing Apoptosis via the Caspase Pathway.

Authors:  Guoxing Ou; Xianyu Jiang; Ang Gao; Xiaolong Li; Zijun Lin; Shimin Pei
Journal:  Front Vet Sci       Date:  2022-02-04

3.  Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus-Positive and Human Papillomavirus-Negative Oropharyngeal Squamous Cell Carcinoma.

Authors:  Hesham Mohamed; Caj Haglund; Lauri Jouhi; Timo Atula; Jaana Hagström; Antti Mäkitie
Journal:  J Histochem Cytochem       Date:  2020-08-14       Impact factor: 2.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.